Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators..

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

2.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators..

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
3.

Atypical acute hemorrhagic leukoencephalitis (Hurst's disease) presenting with focal hemorrhagic brainstem lesion.

Abou Zeid NE, Burns JD, Wijdicks EF, Giannini C, Keegan BM.

Neurocrit Care. 2010 Feb;12(1):95-7. doi: 10.1007/s12028-009-9293-x.

PMID:
19847676
4.

Gait apraxia in multiple sclerosis.

Abou Zeid NE, Weinshenker BG, Keegan BM.

Can J Neurol Sci. 2009 Sep;36(5):562-5.

PMID:
19831123

Supplemental Content

Loading ...
Support Center